Physician profile
Danielle Vanstrien
NPI 1679901540
$1,181.39
in general payments reported to CMS, 2019-2025
18 companies · $279 in 2025
The $279 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $112 · 2022: $262 · 2023: $284 · 2024: $244 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $708 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $707.67 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $226.48 | 2022-2023 | Darzalex, Rybrevant, Imbruvica |
| Astrazeneca Pharmaceuticals LP | $151.06 | 2023-2025 | Tagrisso, Enhertu, Imfinzi |
| Incyte Corporation | $130.48 | 2021-2022 | |
| Daiichi Sankyo INC. | $124.98 | 2023-2025 | Enhertu, Injectafer |
| Abbvie INC. | $114.25 | 2024-2025 | |
| Seagen INC. | $85.64 | 2021-2023 | Tukysa |
| Rigel Pharmaceuticals, INC. | $83.63 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $54.79 | 2021-2024 | Iclusig, Ninlaro |
| Aimmune Therapeutics, INC. | $29.88 | 2025 | Zenpep |
| Adc Therapeutics America, INC. | $26.75 | 2025 | |
| Astellas Pharma Global Development | $25.25 | 2025 | Vyloy |
| Pfizer INC. | $23.88 | 2025 | |
| Progenics Pharmaceuticals, INC. | $23.59 | 2025 | |
| Pharmacyclics LLC, An Abbvie Company | $21.53 | 2022 | |
| Merck Sharp & Dohme LLC | $17.31 | 2024 | Keytruda |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $15.07 | 2024 | Padcev |
| Novocure INC. | $13.75 | 2024 | Optune Lua (Novottf-200t) |
| Gilead Sciences, INC. | $13.07 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Vanstrien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.